ViiV Healthcare To Promote HIV Integrase Inhibitor Dolutegravir Together With Shionogi
This article was originally published in PharmAsia News
Executive Summary
ViiV Healthcare Japan and Shionogi Pharmaceuticals have signed a co-promotion agreement regarding the HIV integrase inhibitor dolutegravir currently awaiting approval from authorities, the companies announced on Dec. 16.